DIA 3rd Cardiac Safety Workshop Explores the Future of the TQT Study And Issues Surrounding the Conduct and Analysis of TQT Studies in Japan

Posted:
9
May 2012

Dr J�rg T�ubel, will be presenting again at the DIA 3rd Cardiac Safety Workshop in Japan, taking place in Tokyo from 28-29 May 2012.The 3rd Cardiac Safety Workshop in Japan will explore topics surrounding the future of the TQT study, including the emerging intensive QT studies, the use of positive controls for assay sensitivity, the risks involved in TQT studies, as well as other issues specific to Japan. The meeting will bring together experts and members of academia, regulatory and drug development organisations for 2 days of intensive discussion, debates and updates.Dr Taubel's extensive experience in investigating ethnic differences and bridging ECG studies exploring physiological and drug induced effects makes him a world leading expert in the evaluation of effects of ethnicity on the ECG. His recent work includes studies in both Caucasian and Japanese participants using techniques such as an euglycaemic insulin clamp investigating the effects of food on the QT interval in a proper ICH E14 setting. He will present some of his latest data.Click here to view the full programWe invite you to be a part of this hugely informative event on current issues facing the industry and network with like-minded scientific professionals. A Business Development representative from Richmond Pharmacology will also be standing by for the duration of the workshop to discuss your prospective TQT study requirements and how we can benefit towards its total success.To arrange a face to face meeting or request a copy of our latest TQT publication,contact a member of our BD Team today.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more